TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Open-label data from the ADAPT SERON trial suggest some people with generalized myasthenia gravis who test negative for AChR antibodies may take longer to show meaningful improvement with intravenous efgartigimod. Neurologist James F. Howard Jr. said clinicians may need to consider three or four treatment cycles before deciding the drug is not helping, while cautioning against continuing ineffective treatment.
Some people with generalized myasthenia gravis who lack detectable acetylcholine receptor antibodies may need three or four cycles of intravenous efgartigimod before clinicians can judge whether it is helping, neurologist James F. Howard Jr. said while discussing open-label ADAPT SERON data. The finding could affect how long clinicians wait before stopping treatment for this group, but the evidence does not establish that every antibody-negative patient will respond with additional cycles.
The ADAPT SERON trial’s open-label data suggest that intravenous efgartigimod, sold as Vyvgart, continued to show efficacy and safety among patients with generalized myasthenia gravis who did not have detectable AChR antibodies. The findings were presented at the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine. The source report does not provide detailed response rates, participant numbers, or a comparison group.
In a MedPage Today interview published October 27, Howard, of the University of North Carolina at Chapel Hill, contrasted this group’s possible response timeline with that seen in the original ADAPT trial. He said most participants in that earlier trial experienced meaningful improvement during the first treatment cycle, whereas some AChR-antibody-negative patients may need two or three cycles before improvement becomes apparent. He suggested clinicians might consider waiting through three or even four cycles—about six months, in his description—before concluding that treatment is not working.
Howard also stressed the need to identify patients who do not benefit, so they are not kept on an ineffective treatment or exposed unnecessarily to potential adverse events. The report describes the ADAPT SERON results as open-label; it does not establish a firm treatment rule or show that extended treatment is appropriate for everyone in this population.
A Longer Trial Before Switching Therapy
The discussion matters because people with generalized myasthenia gravis who test negative for AChR antibodies have had fewer options among targeted therapies, according to Howard. He estimated that this group represents about 10% of the overall patient population, and said some patients also lack identifiable antibodies to MuSK or LRP4. An option that may help some of these patients would address an unmet treatment need.
A slower response could also complicate routine treatment decisions. If clinicians apply expectations drawn from patients who improve in a first cycle, they might stop efgartigimod before a later response appears. But waiting longer has trade-offs: it can delay a change to another approach for patients who will not respond and may expose them to treatment without benefit. The data support careful consideration of response timing, not a blanket instruction to continue therapy for six months.
Products Worth Considering
Blueair Blue Pure 211i Max Smart Air Purifier for Large Rooms
Fitbit Sense Advanced Smartwatch – Sage Grey/Silver (One Size, S & L Bands Included)
Oura Ring 4 Smart Ring – Silver – Size 8
As an affiliate, we earn on qualifying purchases.
Why Antibody Status Matters
Myasthenia gravis is an autoimmune disease affecting communication between nerves and muscles. AChR, MuSK, and LRP4 are among the antibodies clinicians may test for when assessing the disease. Howard described patients without detectable antibodies to these targets as a group that has had limited access to newer targeted treatments. The report calls attention to efgartigimod as a possible treatment avenue, but does not say that the trial findings establish a new approved use or change prescribing guidance.
Howard offered a possible biological explanation for the findings but said it remains uncertain. He noted that AChR antibodies can activate the terminal complement cascade, which can damage the structure of the neuromuscular junction. He said it is not known whether complement activation works the same way in patients with no identifiable antibodies, although he cited basic-science evidence suggesting complement may be present at those junctions. These comments are hypotheses and background, not proof of the mechanism behind a slower response.
“We don’t have the answer and the understanding at this point, it’s being looked at.”
— James F. Howard Jr., MD
Response Timing and Safety Details
The available account does not provide the number of participants, response rates, size of the treatment effect, or detailed safety results for the antibody-negative subgroups. Because the data are described as open-label, the report also does not provide a blinded comparison that would show how outcomes differed against another treatment or control group. It is unclear how many patients needed additional cycles, how consistently later improvement occurred, or which patient characteristics might predict it.
The underlying reason for a slower onset is also unresolved. Howard discussed possible immune mechanisms but said the evidence is not conclusive, particularly for people with no detectable AChR, MuSK, or LRP4 antibodies. His comments about safety are an interview summary, not a complete accounting of risks. Patients should not interpret the suggested timeline as advice to continue or stop treatment without discussion with their treating clinician.
More Data Needed for Treatment Decisions
Further reporting and publication of the ADAPT SERON results could clarify the size and timing of responses, subgroup outcomes, and adverse events. Those details would help clinicians assess whether additional cycles are associated with meaningful benefit and which patients may be most likely to respond. The source report does not specify when a full results paper or additional analysis will be available.
For now, Howard’s comments point to a need to weigh a potentially slower response against the risks of delaying another treatment. Decisions about efgartigimod cycles should be individualized with a clinician, based on a patient’s symptoms, response, and treatment risks; the interview alone does not set a standard duration.
Key Questions
What did the ADAPT SERON data suggest?
The open-label data suggest intravenous efgartigimod showed efficacy and safety in patients with generalized myasthenia gravis who lacked detectable AChR antibodies. The report does not provide detailed response rates or trial statistics.
How long might some patients take to respond?
Howard said some AChR-antibody-negative patients may need two or three cycles before meaningful improvement appears. He suggested clinicians might consider three or four cycles before deciding treatment is not working, but this is not a universal recommendation.
Does this mean patients should stay on efgartigimod for six months?
No. The six-month timeframe was Howard’s suggested consideration based on the reported response pattern. The source does not establish a standard treatment duration, and decisions should be made with the treating clinician.
Why might antibody-negative patients respond later?
The reason is not known. Howard discussed possible differences in immune mechanisms, including complement activation, but said the evidence is still being studied and does not confirm an explanation.
Were new safety problems reported?
Howard said there were no new safety signals in the subgroups discussed. The report does not give detailed adverse-event figures, so it does not provide a full safety analysis.
Source: rss
